Status:
RECRUITING
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
Lead Sponsor:
Vivacelle Bio
Conditions:
Septic Shock
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
Detailed Description
PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia. ST...
Eligibility Criteria
Inclusion
- Male or female at least 18 years of age.
- Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
- Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market.
- Sequential Organ Failure Assessment (SOFA) score ≥ 5
- Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
- Lactate \> 2 mmol/L
- Fever \> 38.3°C, or 101°F
- Hypothermia \< 36°C core temperature (\<96.8°F)
- Heart rate \> 90
- Tachypnea (respiratory rate ≥ 20/min)
- White blood cell count \>12,000 or less than 4,000, or with \>10% "bands" (immature forms)
- Elevated procalcitonin in serum (≥ 2ng/ml)
- Arterial hypoxemia (PaO2/FiO2 \< 300)
- Creatinine increase \> 0.5 mg/dL since hospital admission
- INR \> 1.5 or aPTT \> 60 seconds
- Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
- Receiving vasopressors to maintain the target MAP of 65 mmHg.
Exclusion
- Patients with a ventricular assist device
- Acute coronary syndrome
- Pregnant
- Acute bronchospasm
- Acute Mesenteric ischemia
- Emergency major surgery
- Diagnosis of acute Hepatitis B or C.
- Hematologic or coagulation disorders including thrombocytopenia (platelet count \<50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.
- White blood cell count of \< 1000 mm3
- Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.
- Patients with a known allergy to soybeans or eggs
- Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.
- Patient expected to expire within 12 hours.
- Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.
Key Trial Info
Start Date :
August 6 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06072430
Start Date
August 6 2024
End Date
December 1 2025
Last Update
April 4 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Dignity Health Chandler Regional Medical Center
Chandler, Arizona, United States, 85224
2
Memorial Health University Medical Center
Savannah, Georgia, United States, 31404
3
University Health
Kansas City, Missouri, United States, 64108
4
Bryan Medical Center
Lincoln, Nebraska, United States, 68506